Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, octubre 30
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Vaxcyte Inc
PCVX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$62.00
-0.61
-0.97%
Últ. Act.: Oct 30, 9:09 AM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Vaxcyte Financials
Vaxcyte (PCVX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Stock Market Today: S&P 500, Dow Jones Futures Gain as Scott Bessent Doubles Down on Iran Pressure— OPCH, PCVX, STZ in Focus
U.S. stock futures were higher on Tuesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, following Monday's higher close.
Rishabh Mishra
PRO
Vaxcyte Q2 EPS $(1.97) Beats $(2.22) Estimate
Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.97) per share which beat the analyst consensus estimate of $(2.22) by 11.26 percent. This is a 61.48 percent decrease over losses of $(1.22) per share from the same
Benzinga Newsdesk
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
Vaxcyte Q1 EPS $(2.30) Misses $(1.82) Estimate
Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(2.30) per share which missed the analyst consensus estimate of $(1.82) by 26.37 percent. This is a 121.15 percent decrease over losses of $(1.04) per share from the
Benzinga Newsdesk
PRO
Vaxcyte Q4 EPS $(1.80) Misses $(1.56) Estimate
Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.80) per share which missed the analyst consensus estimate of $(1.56) by 15.38 percent. This is a 76.47 percent decrease over losses of $(1.02) per share from the
Benzinga Newsdesk
Earnings Scheduled For February 24, 2026
Benzinga Insights
